Overview of Novel Biomarkers for Management of Postchemotherapy Residual Masses in Testicular Cancer.

Ding, Renjie; Li, Xiangdong; Liu, Zhuowei

Ding, Renjie; Li, Xiangdong; Liu, Zhuowei.

Afiliación

Ding R; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Li X; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Liu Z; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: liuzhw@sysucc.org.cn.

Eur Urol Focus ; 2024 May 08.

Article en En | MEDLINE | ID: mdl-38724341

ABSTRACT

ABSTRACT

The diagnosis of postchemotherapy residual masses in testicular cancer must be based on the integration of clinical, imaging, and serology tests. Further validation is needed for novel biomarkers.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur Urol Focus Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google